Agonists targeting the receptors of incretin hormones, glucagon like peptide-1 (GLP-1)andglucose-dependent insulinotropic peptide, have been well established for the treatment of type 2diabetesmellitus. There is increasing awareness that gastroenterologists and hepatologists should be treating obesity when patients present to their clinics.
Here, we used d -allulose, a nonmetabolizable noncaloric rare sugar, as aGLP-1secretagogue. We show that d -allulose-induced intestinalGLP-1secretion (AIGS) cooperates with insulin to reduce blood glucose levels by enhancing insulin action, rather than insulin secretion, in male mice.
As we can see from the illustration, Glp-1 And Gut Function In Diabetes has many fascinating aspects to explore.
Baselinegutmicrobiota composition may influence individual responses toGLP-1receptor agonists and SGLT-2 inhibitors, supporting the potential for microbiota-informed personalized treatment strategies in type 2diabetes.
GLP-1analogues have demonstrated a notable impact on the composition, richness, and diversity ofgutmicrobiota. We can conclude, following the obtained research results of our study, that liraglutide promotes the growth of beneficial genera relevant for beneficial metabolicfunctions.
Glucagon-like peptide-1 (GLP-1) is produced ingutendocrine cells and in the brain, and acts through hormonal and neural pathways to regulate isletfunction, satiety, andgutmotility, supporting development ofGLP-1receptor (GLP-1R) agonists for the treatment ofdiabetesandobesity.
Patient selection - GLP-1-based therapies are particularly appropriate for use alone or in combination with other glucose-lowering agents in certain clinical settings that include the following [22,23] (see 'Patient selection' above and "Management of persistent hyperglycemia in type 2diabetesmellitus", section on 'Our approach'):
 "How diet, sleep and gut health impact GLP-1 and weight regulation ...")
